Market capitalization | CHF188.16b |
Enterprise Value | CHF204.02b |
PER (TTM) P/E ratio | 14.63 |
EV/FCF (TTM) EV/FCF | 18.05 |
EV/Sales (TTM) EV/Sales | 4.73 |
P/S ratio (TTM) P/S ratio | 4.36 |
P/B ratio (TTM) P/B ratio | 5.49 |
Dividend yield | 3.43% |
Last dividend (FY23) | CHF3.30 |
Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.
29 Analysts have issued a Novartis forecast:
29 Analysts have issued a Novartis forecast:
Mar '24 |
+/-
%
|
||
Turnover | 43,132 43,132 |
11%
11%
|
|
Gross income | 31,108 31,108 |
8%
8%
|
|
EBITDA | 18,755 18,755 |
4%
4%
|
EBIT (operating result) EBIT | 11,808 11,808 |
2%
2%
|
Net profit | 13,512 13,512 |
102%
102%
|
Figures in millions CHF.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Vasant Narasimhan |
Employees | 76,057 |
Founded | 1996 |
Website | www.novartis.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.